130 related articles for article (PubMed ID: 38778824)
1. Carbon Ion Radiation Therapy for Nonmetastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis.
Miyasaka Y; Kawamura H; Sato H; Kubo N; Katoh H; Ishikawa H; Matsui H; Miyazawa Y; Ito K; Suzuki K; Ohno T
Adv Radiat Oncol; 2024 Apr; 9(4):101432. PubMed ID: 38778824
[TBL] [Abstract][Full Text] [Related]
2. Carbon ion radiotherapy for prostate cancer with bladder invasion.
Miyasaka Y; Kawamura H; Sato H; Kubo N; Mizukami T; Matsui H; Miyazawa Y; Ito K; Nakano T; Suzuki K; Ohno T
BMC Urol; 2021 Aug; 21(1):106. PubMed ID: 34362355
[TBL] [Abstract][Full Text] [Related]
3. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract][Full Text] [Related]
4. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
[TBL] [Abstract][Full Text] [Related]
6. Salvage Carbon Ion Radiation Therapy for Locally Recurrent or Radiation-Induced Second Primary Sarcoma of the Head and Neck.
Yang J; Gao J; Wu X; Hu J; Hu W; Kong L; Lu JJ
J Cancer; 2018; 9(12):2215-2223. PubMed ID: 29937942
[No Abstract] [Full Text] [Related]
7. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
Sato H; Kasuya G; Ishikawa H; Nomoto A; Ono T; Nakajima M; Isozaki Y; Yamamoto N; Iwai Y; Nemoto K; Ichikawa T; Tsuji H;
Cancer Sci; 2021 Sep; 112(9):3598-3606. PubMed ID: 34107139
[TBL] [Abstract][Full Text] [Related]
8. Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer.
Takakusagi Y; Katoh H; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Kamada T
Radiat Oncol; 2020 May; 15(1):127. PubMed ID: 32460889
[TBL] [Abstract][Full Text] [Related]
9. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
[TBL] [Abstract][Full Text] [Related]
10. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease.
Henriquez I; Spratt D; Gómez-Iturriaga A; Abuchaibe O; Couñago F
World J Clin Oncol; 2021 Jan; 12(1):6-12. PubMed ID: 33552935
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma.
Kong L; Hu J; Guan X; Gao J; Lu R; Lu JJ
J Cancer; 2016; 7(7):774-83. PubMed ID: 27162535
[TBL] [Abstract][Full Text] [Related]
12. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
[TBL] [Abstract][Full Text] [Related]
13. Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Li M; Li X; Yao L; Han X; Yan W; Liu Y; Fu Y; Wang Y; Huang M; Zhang Q; Wang X; Yang K
Front Oncol; 2021; 11():709530. PubMed ID: 34712607
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer.
Takakusagi Y; Oike T; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Katoh H; Kamada T
PLoS One; 2020; 15(11):e0241636. PubMed ID: 33156884
[TBL] [Abstract][Full Text] [Related]
15. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
17. Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by and the Japan carbon-ion radiation oncology study group (J-CROS).
Kasuya G; Terashima K; Shibuya K; Toyama S; Ebner DK; Tsuji H; Okimoto T; Ohno T; Shioyama Y; Nakano T; Kamada T;
Oncotarget; 2019 Jul; 10(43):4369-4379. PubMed ID: 31320991
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
[TBL] [Abstract][Full Text] [Related]
19. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study.
Wang Y; Liu C; Liu C; Lu Y; Ban L; Niu Y
J Med Econ; 2024; 27(1):361-369. PubMed ID: 38375556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
